Dongxing Medical announced that it plans to purchase 90% of the shares of Wuhan Yijiabao Biomaterials Co., Ltd. through cash payment. If the transaction is successfully implemented, Wuhan Medical Jiabao will become the company's holding subsidiary. The transaction is expected to constitute a major asset restructuring as stipulated in the “Administrative Measures on Major Asset Restructuring of Listed Companies”. This transaction does not involve the issuance of shares by a listed company, does not constitute a related transaction, and will not result in changes in the controlling shareholders and actual controllers of the listed company.

Dongxing Medical announced that it plans to purchase 90% of the shares of Wuhan Yijiabao Biomaterials Co., Ltd. through cash payment. If the transaction is successfully implemented, Wuhan Medical Jiabao will become the company's holding subsidiary. The transaction is expected to constitute a major asset restructuring as stipulated in the “Administrative Measures on Major Asset Restructuring of Listed Companies”. This transaction does not involve the issuance of shares by a listed company, does not constitute a related transaction, and will not result in changes in the controlling shareholders and actual controllers of the listed company.